The role of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease / 中华内分泌代谢杂志
Chinese Journal of Endocrinology and Metabolism
;
(12): 1017-1020, 2014.
Artículo
en Chino
| WPRIM
| ID: wpr-469947
ABSTRACT
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin-based drugs for type 2diabetes.In recent years,it has been proven in clinical practices that GLP-1 receptor agonists have protection effect beyond anti-hyperglycemic effects,such as improvement of non-alcoholic fatty liver disease (NAFLD).The cogent evaluation,understanding,and exploration of therapeutic effect and mechanism of GLP-1 receptor agonists in NAFLD are important.Besides,it would be of great significance to identify pathogenesis of diabetes,its correlation with NAFLD,and the development of new drugs.This article briefly reviews the therapeutic effect of GLP-1 receptor agonists on NAFLD.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Endocrinology and Metabolism
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS